Drug fails at phase III in uveal melanoma
Sanofi will pay more than $2bn to the firm for immunotherapy research
New survey finds people would rather self-diagnose symptoms rather than wait for GP appointment
Will now drop its six-month pursuit of Mylan
New drugs for ADHD and haemophilia backed for
decision puts firm on-course to catch up with Amgen's Repatha
Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals
French firm’s rare disease unit Genzyme will pay $300m for the treatment
will create over 100 new drug discovery jobs
Identifying opportunities and taking advantage of them
The EMA's scientific advisers recommend its use
Grwoth expected to come from new treatments and the condtion's rising prevalence
New and old cancer drugs boost revenue for the Swiss pharma firm
Expectations remain high but high efficacy rates still allusive for most firms
Merck’s new PD-1 drug will compete against rival BMS for market share
Comes after a difficult two years for the silo budget
court's complex ruling could have a wide-ranging impact
Company expands leadership team with former Takeda VP
Research head will be first member of a new cancer-focused firm
Moves from Ipsos MORI to take up role as senior
He will succeed Dr Jean-Paul Kress at
the Sanofi Pasteur - Merck & Co venture
Will take up commercial role at UK pharma body
at the end of the month
Subscribe to our email news alerts
Why tugging at our heartstrings is no longer enough to make us open our purses
- Charlotte Shyllon (Director and Partner) and Maren Thurow (Senior Account Executive), discuss the highly emotive Make a Child Cry campaign video from Doctors of the World (Médecins du Monde)....
- Exploring full potential of e-detailing data
- Today’s high quality e-detailing data can create better quality conversations with healthcare professionals and result in improved access and relationships....
Understanding the "Big Picture"
- In this article, Nic Talbot-Watt, Director of Analysis and Forecasting at Black Swan Analysis, highlights the advantage of having a robust commercial understanding of their healthcare innovation early in the...